Top Buy Stocks
Sign In
Invest in CASI
$1.89
-0.0301 (-1.57%)
At Close: May 22, 2025
CASI Pharmaceuticals Provides Business and Clinical Update
09:00am, Monday, 19'th May 2025
BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commerc
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
08:00am, Friday, 16'th May 2025
BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercial
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
08:00am, Monday, 12'th May 2025
BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commerc
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
08:00am, Wednesday, 07'th May 2025
BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commerci
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
08:00am, Thursday, 03'rd Apr 2025
BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative t
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
08:15am, Monday, 31'st Mar 2025
BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and comme
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
08:00am, Monday, 06'th Jan 2025
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic an
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
08:00am, Friday, 15'th Nov 2024
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development an
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
08:00am, Thursday, 24'th Oct 2024
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic a
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
08:00am, Wednesday, 04'th Sep 2024
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commerc
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
08:00am, Friday, 16'th Aug 2024
BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commerc
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
03:04pm, Monday, 29'th Jul 2024
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
05:30pm, Friday, 19'th Jul 2024
BEIJING , July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
07:30am, Monday, 08'th Jul 2024
BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
10:45am, Thursday, 27'th Jun 2024
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
